202 related articles for article (PubMed ID: 20388851)
1. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma.
Lee JW; Stone RL; Lee SJ; Nam EJ; Roh JW; Nick AM; Han HD; Shahzad MM; Kim HS; Mangala LS; Jennings NB; Mao S; Gooya J; Jackson D; Coleman RL; Sood AK
Clin Cancer Res; 2010 May; 16(9):2562-70. PubMed ID: 20388851
[TBL] [Abstract][Full Text] [Related]
2. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
Lee JW; Han HD; Shahzad MM; Kim SW; Mangala LS; Nick AM; Lu C; Langley RR; Schmandt R; Kim HS; Mao S; Gooya J; Fazenbaker C; Jackson D; Tice DA; Landen CN; Coleman RL; Sood AK
J Natl Cancer Inst; 2009 Sep; 101(17):1193-205. PubMed ID: 19641174
[TBL] [Abstract][Full Text] [Related]
3. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.
Jackson D; Gooya J; Mao S; Kinneer K; Xu L; Camara M; Fazenbaker C; Fleming R; Swamynathan S; Meyer D; Senter PD; Gao C; Wu H; Kinch M; Coats S; Kiener PA; Tice DA
Cancer Res; 2008 Nov; 68(22):9367-74. PubMed ID: 19010911
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.
Merritt WM; Kamat AA; Hwang JY; Bottsford-Miller J; Lu C; Lin YG; Coffey D; Spannuth WA; Nugent E; Han LY; Landen CN; Nick AM; Stone RL; Coffman K; Bruckheimer E; Broaddus RR; Gershenson DM; Coleman RL; Sood AK
Cancer Biol Ther; 2010 Dec; 10(12):1306-14. PubMed ID: 20948320
[TBL] [Abstract][Full Text] [Related]
5. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
Bruckheimer EM; Fazenbaker CA; Gallagher S; Mulgrew K; Fuhrmann S; Coffman KT; Walsh W; Ready S; Cook K; Damschroder M; Kinch M; Kiener PA; Woods R; Gao C; Dall'Acqua W; Wu H; Coats S
Neoplasia; 2009 Jun; 11(6):509-17, 2 p following 517. PubMed ID: 19484140
[TBL] [Abstract][Full Text] [Related]
6. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer.
Dasari SK; Joseph R; Umamaheswaran S; Mangala LS; Bayraktar E; Rodriguez-Aguayo C; Wu Y; Nguyen N; Powell RT; Sobieski M; Liu Y; Chowdhury MA; Amero P; Stephan C; Lopez-Berestein G; Westin SN; Sood AK
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835335
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
8. CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma.
Nakae R; Matsuzaki S; Serada S; Matsuo K; Shiomi M; Sato K; Nagase Y; Matsuzaki S; Nakagawa S; Hiramatsu K; Okazawa A; Kimura T; Egawa-Takata T; Kobayashi E; Ueda Y; Yoshino K; Naka T; Kimura T
Am J Obstet Gynecol; 2021 Feb; 224(2):197.e1-197.e23. PubMed ID: 32822640
[TBL] [Abstract][Full Text] [Related]
9. Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design.
Lee NK; Su Y; Bidlingmaier S; Liu B
Mol Cancer Ther; 2019 Jun; 18(6):1092-1103. PubMed ID: 30962321
[TBL] [Abstract][Full Text] [Related]
10. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer.
Wu Y; Huang J; Ivan C; Sun Y; Ma S; Mangala LS; Fellman BM; Urbauer DL; Jennings NB; Ram P; Coleman RL; Hu W; Sood AK
Gynecol Oncol; 2021 Oct; 163(1):181-190. PubMed ID: 34391578
[TBL] [Abstract][Full Text] [Related]
11. Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.
Roh JW; Huang J; Hu W; Yang X; Jennings NB; Sehgal V; Sohn BH; Han HD; Lee SJ; Thanapprapasr D; Bottsford-Miller J; Zand B; Dalton HJ; Previs RA; Davis AN; Matsuo K; Lee JS; Ram P; Coleman RL; Sood AK
Clin Cancer Res; 2014 May; 20(10):2740-50. PubMed ID: 24634380
[TBL] [Abstract][Full Text] [Related]
12. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer.
Joseph R; Dasari SK; Umamaheswaran S; Mangala LS; Bayraktar E; Rodriguez-Aguayo C; Wu Y; Nguyen N; Powell RT; Sobieski M; Liu Y; Kim MS; Corvigno S; Foster K; Hanjra P; Vu TC; Chowdhury MA; Amero P; Stephan C; Lopez-Berestein G; Westin SN; Sood AK
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279277
[TBL] [Abstract][Full Text] [Related]
13. Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
Perrone E; Manara P; Lopez S; Bellone S; Bonazzoli E; Manzano A; Zammataro L; Bianchi A; Zeybek B; Buza N; Tymon-Rosario J; Altwerger G; Han C; Menderes G; Huang GS; Ratner E; Silasi DA; Azodi M; Hui P; Schwartz PE; Scambia G; Santin AD
Mol Oncol; 2020 Mar; 14(3):645-656. PubMed ID: 31891442
[TBL] [Abstract][Full Text] [Related]
14. MMAE Delivery Using the
Bennett G; Brown A; Mudd G; Huxley P; Van Rietschoten K; Pavan S; Chen L; Watcham S; Lahdenranta J; Keen N
Mol Cancer Ther; 2020 Jul; 19(7):1385-1394. PubMed ID: 32398269
[TBL] [Abstract][Full Text] [Related]
15. Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor.
Nishimura T; Nakamura K; Yamashita S; Ikeda S; Kigure K; Minegishi T
BMC Cancer; 2015 Dec; 15():957. PubMed ID: 26673416
[TBL] [Abstract][Full Text] [Related]
16. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
Tse KF; Jeffers M; Pollack VA; McCabe DA; Shadish ML; Khramtsov NV; Hackett CS; Shenoy SG; Kuang B; Boldog FL; MacDougall JR; Rastelli L; Herrmann J; Gallo M; Gazit-Bornstein G; Senter PD; Meyer DL; Lichenstein HS; LaRochelle WJ
Clin Cancer Res; 2006 Feb; 12(4):1373-82. PubMed ID: 16489096
[TBL] [Abstract][Full Text] [Related]
17. PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor.
Jacobson O; Li Q; Chen H; Niu G; Kiesewetter DO; Xu L; Cook K; Yang G; Dall'Acqua W; Tsui P; Peng L; Chen X
J Nucl Med; 2017 Nov; 58(11):1838-1844. PubMed ID: 28546337
[TBL] [Abstract][Full Text] [Related]
18. Novel anti-EPHA2 antibody, DS-8895a for cancer treatment.
Hasegawa J; Sue M; Yamato M; Ichikawa J; Ishida S; Shibutani T; Kitamura M; Wada T; Agatsuma T
Cancer Biol Ther; 2016 Nov; 17(11):1158-1167. PubMed ID: 27653549
[TBL] [Abstract][Full Text] [Related]
19. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer.
Bourillon L; Bourgier C; Gaborit N; Garambois V; Llès E; Zampieri A; Ogier C; Jarlier M; Radosevic-Robin N; Orsetti B; Delpech H; Theillet C; Colombo PE; Azria D; Pèlegrin A; Larbouret C; Chardès T
Int J Cancer; 2019 Oct; 145(7):1838-1851. PubMed ID: 30882895
[TBL] [Abstract][Full Text] [Related]
20. [Effect of signal transduction inhibitors on human endometrial carcinoma cells with differential PTEN gene expression].
Xiao L; Yang YB; Shen HM; Xu CF; Wang XY; Li XM
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):681-5. PubMed ID: 20079181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
